scholarly journals Clinical and immunological responses in sheep after inoculation with Himar1-transformed Anaplasma phagocytophilum and subsequent challenge with a virulent strain of the bacterium

2021 ◽  
Vol 231 ◽  
pp. 110165
Author(s):  
Sveinung Eskeland ◽  
Snorre Stuen ◽  
Ulrike G. Munderloh ◽  
Anthony Barbet ◽  
Liliana Crosby ◽  
...  
2007 ◽  
Vol 74 (3) ◽  
pp. 219-226
Author(s):  
M. Nishizawa ◽  
A.C. Paulillo ◽  
A. Bernardino ◽  
A.C. Alessi ◽  
S. Sayd ◽  
...  

ABSTRACT The study was divided into three experiments. In the first one, broilers were distributed into six groups and vaccinated against infectious bursal disease at 14 days of age: T1-not vaccinated, T2-Lukert1 (intermediate), T3-Lukert2 (intermediate plus), T4-228E, T5-V877 and T6-Winterfield 2512 (“hot” strains). Bursas of Fabricius (BF) were collected at 17, 21, 28 and 35 days to measure BF relative weight (BFRW), diameter, histological examination and image processing analysis (IPA). At one, 14, 21, 28 and 35 days of age, samples of blood taken from eight birds from each group for serology analysis by ELISA test. Hot strains vaccines induced reduction of BFRW and BF diameter, higher histological score lesion degree, more lymphocyte depletion on the BF follicles and higher IBD antibody titer. In the second experiment, 16 birds from groups T1 to T6 were isolated and challenged with a very virulent strain of IBDV (vvIBDV) at 25 days of age. Only groups T4, T5 and T6 were totally protected against vvIBDV challenge. In the third experiment, the immunosuppressive potential of each vaccine was determined by examining the ability of IBDVvaccinated birds to respond to Newcastle disease (ND) vaccination and challenge. None of the vaccines was found to be immunodepressive.


1997 ◽  
Vol 2 (5) ◽  
pp. 482-487 ◽  
Author(s):  
Claudio Zuniga ◽  
Teresa Palau ◽  
Pilar Penin ◽  
Carlos Gamallo ◽  
Jose Antonio de Diego

2018 ◽  
Vol 11 (3) ◽  
pp. 149-154
Author(s):  
Eman Gaballah ◽  
Aida Abdel-Magied ◽  
Nora Aboulfotouh ◽  
Goman Elganainy

2019 ◽  
Vol 19 (8) ◽  
pp. 633-644 ◽  
Author(s):  
Komal Kalani ◽  
Sarfaraz Alam ◽  
Vinita Chaturvedi ◽  
Shyam Singh ◽  
Feroz Khan ◽  
...  

Introduction: As a part of our drug discovery program for anti-tubercular agents, dihydroartemisinin (DHA-1) was screened against Mtb H37Rv, which showed moderate anti-tubercular activity (>25.0 µg/mL). These results prompted us to carry out the chemical transformation of DHA-1 into various derivatives and study their antitubercular potential. Materials and Methods: DHA-1 was semi-synthetically converted into four new acyl derivatives (DHA-1A – DHA-1D) and in-vitro evaluated for their anti-tubercular potential against Mycobacterium tuberculosis H37Rv virulent strain. The derivatives, DHA-1C (12-O-(4-nitro) benzoyl; MIC 12.5 µg/mL) and DHA-1D (12-O-chloro acetyl; MIC 3.12µg/mL) showed significant activity against the pathogen. Results: In silico studies of the most active derivative (DHA-1D) showed interaction with ARG448 inhibiting the mycobacterium enzymes. Additionally, it showed no cytotoxicity towards the Vero C1008 cells and Mouse bone marrow derived macrophages. Conclusion: DHA-1D killed 62% intracellular M. tuberculosis in Mouse bone marrow macrophage infection model. To the best of our knowledge, this is the first-ever report on the antitubercular potential of dihydroartemisinin and its derivatives. Since dihydroartemisinin is widely used as an antimalarial drug; these results may be of great help in anti-tubercular drug development from a very common, inexpensive, and non-toxic natural product.


Sign in / Sign up

Export Citation Format

Share Document